Tay-Sachs disease (TSD) is a lethal lysosomal storage disease (LSD) caused by mutations in the HexA gene, which can lead to deficiency of β-hexosaminidase A (HexA) activity and consequent accumulation of its substrate, GM2 ganglioside. Recent reports that progranulin (PGRN) functions as a chaperone of lysosomal enzymes and its deficiency is associated with LSDs, including Gaucher disease and neuronal ceroid lipofuscinosis, prompted us to screen the effects of recombinant PGRN on lysosomal storage in fibroblasts from 11 patients affected by various LSDs, which led to the isolation of TSD in which PGRN demonstrated the best effects in reducing lysosomal storage. Subsequent in vivo studies revealed significant GM2 accumulation and the existence of typical TSD cells containing zebra bodies in both aged and ovalbumin-challenged adult PGRN-deficient mice. In addition, HexA, but not HexB, was aggregated in PGRN-deficient cells. Furthermore, recombinant PGRN significantly reduced GM2 accumulation and lysosomal storage in these animal models. Mechanistic studies indicated that PGRN bound to HexA through granulins G and E domain and increased the enzymatic activity and lysosomal delivery of HexA. More importantly, Pcgin, an engineered PGRN derivative bearing the granulin E domain, also effectively bound to HexA and reduced the GM2 accumulation. Collectively, these studies not only provide new insights into the pathogenesis of TSD but may also have implications for developing PGRN-based therapy for this life-threatening disorder.
Introduction
Tay-Sachs disease (TSD), a subtype of the GM2 gangliosidoses, is an inherited autosomal recessive disease caused by mutations of the gene encoding the α-subunit of β-hexosaminidase A (HexA) that result in the deficiency of the enzyme and the accumulation of its specific substrate, GM2 ganglioside, mainly in the central nervous system [1] [2] [3] . The clinical signs and pathologic features of TSD were first described in 1887 according to the combined descriptions of the disease by physicians Warren Tay and Bernard Sachs [3] . Clinical presentation of TSD can be categorized across three subtypes: acute infantile TSD, juvenile (subacute) TSD, and chronic or adult-onset TSD [4] . Acute infantile TSD is the most common and aggressive variant with presentation and death occurring in early infancy. Relative to the acute infantile form of the disease, juvenile and adult-onset TSD are rare and have greater variability in neurological presentation. Juvenile (subacute) TSD manifests symptomatically during the first years of childhood and, like acute infantile TSD, is fatal. Adult-onset TSD exists as a milder form, and those affected can survive to adulthood [4] .
In the general population of the USA, the incidence of TSD is 1 in 320,000 births; however, incidence of unaffected TSD carriers may reach 1 in 250 births. The Ashkenazi Jewish represent a disproportionately affected subpopulation in which TSD incidence is 1 in 3600 births in general population and 1 in 30 in unaffected carriers [4] [5] [6] . Although preventative screening for TSD has progressed, no curative or diseasemodifying therapies are currently available for TSD, and best practices for disease management are limited to supportive care measures [3, 7] . Advancements in the understanding of the genetic and pathophysiological basis of TSD have led to the suggestion of several potential treatment strategies including enzyme replacement, substrate reduction therapy, pharmacologic chaperone therapy, cellular infusions, and bone marrow transplantation; these strategies are still under investigation [8] [9] [10] .
Progranulin (PGRN), a 593 amino acid secreted glycoprotein and pleiotropic growth factor-like molecule is widely expressed in distinct tissues and in multiple cell populations, including epithelial, immune, neuronal, chondrocyte, and hematopoietic cells [11] [12] [13] [14] [15] . PGRN has well-accepted roles in cell proliferation, migration, and survival and has demonstrated involvement in pathophysiological processes of inflammation, tumorigenesis, wound healing and tissue repair, bone formation and remodeling, immune disease, atherosclerosis, and neurodegenerative diseases [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Evidence also suggests that PGRN is crucial in maintaining lysosomal homeostasis. Our recent studies have revealed that PGRN functions as a chaperone molecule to facilitate glucocerebrosidase (GCase) traffic to lysosome, and its deficiency leads to a GD phenotype, including the appearance of lipid-engorged Gaucher cells in mice [28] . Moreover, treatment with either PGRN or its small derivative, Pcgin, is able to ameliorate GD phenotype through protein disaggregation in patient fibroblasts and GD model mice [29] . These findings support a role of PGRN as a disease-modifying co-factor in GD [28] [29] [30] and raise the question of whether PGRN's chaperone functionality is a general mechanism applicable to multiple lysosomal enzymes [31] . Herein, we screened multiple LSDs and identified TSD as additional LSD in which PGRN showed promising therapeutic effects.
Methods

Mice
All mice were housed in the Skirball Animal Facility of New York University Langone Medical Center. All animal experiments have been performed in accordance with protocols approved for ethical implementation (protocol ID: 160605-03) by the Institutional Animal Care and use Committee (IACUC) of New York University School of Medicine. All mice were maintained on a C57BL/6 background; genotyping of PGRN knockout (KO) mice and wild-type (WT) litter mates was performed as described previously [11, 22, 32] . Eight-weekold WT and PGRN KO mice and 1-year-old WT and PGRN KO aged mice were used for the experiments.
Reagents and material
Lipid lysate preparation
The preparation of lipid lysate has been described previously [28, 29] . Following killing by cervical dislocation, brain tissue was aseptically collected from a C57BL/6 mouse. The brain tissue was weighed and cut into small pieces using a sterile scalpel before homogenization in DMEM. Following homogenization, additional DMEM was added to adjust the concentration to 10 mg ml
Construction of expression plasmids
The construction of the plasmids containing PGRN, its Cterminal deletions (CD), its N-terminal deletions (ND), and the six deletion mutants of Pcgin were described previously [29] . In short, the CD constructs were CD1 (aa 1-521), CD2 (aa 1-444), CD3 (aa 1-376), CD4 (aa 1-284), CD5 (aa 1-209), CD6 (aa 1-127), and CD7 (aa 1-61). The ND constructs were ND1 (aa 45-593), ND2 (aa 113-593), ND3 (aa 179-593), ND4 (aa 261-593), ND5 (aa 336-593), ND6 (aa 416-593), and ND7 (aa 496-593). The six Pcgin deletion mutants were as follows: Δ1 deleted aa 496-522, Δ2 deleted aa 523-534, Δ3 deleted aa 535-539, Δ4 deleted aa 540-573, Δ5 deleted aa 574-593, and Δ6 deleted the last three QLL amino acids.
Treatment effect of PGRN or Pcgin in LSD assessed by fluorescent microscope
Patient fibroblasts were seeded on cover glasses in 24-well plates and treated with PBS (ctrl group), lipid lysis of brain lysate (50 μg ml −1 ), PGRN (0.5 μg ml −1 ), or Pcgin
) for 24 h. Cells were stained with LysoTracker Red at the concentration of 300 nM and incubated at 37°C for 1 h. Cells were washed twice with PBS and fixed in 4% paraformaldehyde (PFA) for 10 min. The cover glasses were mounted on slides with DAPI. The red fluorescence of lysosomes was visualized by fluorescent microscopy. Ten images were randomly taken for each sample, and fluorescent intensities were quantified by ImageJ software.
Fluorescent intensity quantified by plate reader
Patient-derived fibroblasts were seeded in 96-well plates. After the treatment with lipid lysates (50 μg ml ) for 24 h, medium was replaced with fresh medium containing newly made LysoTracker Red (300 nM) and plates were incubated at 37°C for 1 h. After aspirating the medium, washing with PBS once, and adding 100 μl PBS, plates were read using the SpectraMax i3x system at 559 nm for excitation and 601 nm for emission. cells for 24 h. Cells were lysed by RIPA lysis, and a total of 1 mg protein was used to conduct co-immunoprecipitation (Co-IP) in each sample. Anti-His antibody was used to perform immunoprecipitation, and GFP antibody was used to probe the protein complex.
GM2 analysis by mass spectrometry
Mice brain tissues from different groups were collected when mice were killed. The brain tissues were processed at lipid core facility at Cincinnati Children's Hospital Medical Center to analyze GM2 levels as reported previously [13] .
HexA enzymatic activity
Fibroblasts were seeded in 96-well plates. After the treatment, cells were washed twice with PBS, followed by adding 10 mM citrate 60 μl −1 phosphate (pH 4.2) buffer, containing 0.5% human serum albumin and 0.5% Triton X-100, for 20 min on a shaker to lyse the cells. 25 μl of 3.2 mM MUGS was added to the cell lysate and incubated at 37°C for 1 h. The reaction was stopped by adding 200 μl 0.1 M 2-amino-2-methyl-1-propanol, pH 10.5, and fluorescence was measured at an excitation wavelength of 365 nm and emission wavelength of 450 nm [34, 35] .
Western blot
Cells were lysed on ice using RIPA lysis buffer, and protein concentrations were quantified by BCA assay. Samples were boiled for 5 min in SDS sample buffer. Proteins were run on a 12% SDSpolyacrylamide gel and electrotransferred onto a 0.45-μm nitrocellulose membrane. After blocking in 5% nonfat dry milk in Tris buffer-saline-Tween 20 (10 mM Tris-HCl, pH 8.0; 150 mM NaCl; and 0.5% Tween 20; TBS-T) for 30 min, blots were incubated with primary antibody for 2 h. Following three washes in TBS-T for 5 min each time, the blots were incubated with secondary antibody (horseradish peroxidase conjugated immunoglobulin) for 1 h. After washing, visualization of the bound antibody was performed by an enhanced chemiluminescence system (Amersham Life Science, Arlington Heights, IL, USA).
Ovalbumin induced Tay-Sachs disease mouse model
All animal work was completed in accordance with procedures approved for ethical implementation by the New York University School of Medicine IACUC (protocol ID: 160605-03). Eight-week-old C57BL/6 PGRN KO mice were used to establish TSD models through intraperitoneal (IP) injection of ovalbumin (OVA) on days 1 and 15 [36] . Intranasal challenge with 1% OVA was administered beginning at day 29 and continuing for 4 weeks at a frequency of once every 3 days. PBS, PGRN (4 mg kg
), or Pcgin (4 mg kg
) were administered via IP injection for 4 weeks beginning at day 29 (n = 6 in each group) to test the treatment effects of recombinant PGRN and Pcgin in TSD mouse models. After 4 weeks, mice were killed and brain tissues were fixed and processed by Mass Histology Service (Worcester, MA, USA).
Transmission electron microscope
After OVA treatment, PGRN KO mice were anesthetized and the lung was perfused with fixative containing 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 2 h. After washing, the samples were postfixed in 1% OsO 4 for 1 h, followed by block staining with 1% uranyl acetate for 1 h. After dehydration, samples were embedded in Embed 812 (Electron Microscopy Sciences, Hatfield, PA, USA). Sixty-nanometer sections were cut and stained with uranyl acetate and lead citrate by standard methods. Stained grids were examined under a Philips CM-12 electron microscope (FEI; Eindhoven, Netherlands) and photographed with a Gatan (4 k × 2.7 k) digital camera (Gatan, Inc., Pleasanton, CA, USA).
Immunohistochemistry of GM2
Paraffin-embedded brain slides were deparaffinized in a xylene and ethanol gradient. After antigen retrieval by 0.1% trypsin in DMEM and depletion of endogenous hydrogen peroxidase, the slides were blocked with 3% BSA and 20% goat serum for 30 min at room temperature. GM2 antibody in 2% goat serum (1:200) was incubated at 4°C overnight. After washing with PBS, secondary antibodies were added (1:200) for 1 h at 37°C. The staining was visualized with Vector ABC peroxidase kit with DAB as chromagen followed by counter staining and rehydration.
Immunofluorescence staining of GM2
Paraffin-embedded brain sections from PGRN KO mice with OVA challenge were deparaffinized in a xylene and ethanol gradient. After antigen retrieval by 0.1% trypsin in DMEM, slides were fixed with 4% formaldehydrate for 10 min at room temperature, permeabilized by 0.1% Triton X-100 in PBS for 5 min at room temperature and blocked with donkey serum in PBS (1:50) for 1 h at room temperature. GM2 antibody diluted in blocking buffer (1:200) was added at 4°C overnight, followed by fluorescence-labeled secondary antibodies in blocking buffer (1:200) at 37°C for 1 h. After washing with PBS three times, the tissues were mounted with DAPI. The images were taken by immunofluorescence microscope.
Frozen brain sections from PGRN KO mice challenged with OVA were co-stained with GM2 antibody, as well as neuronal marker (NeuN antibody) or microglial marker (CD68) or astrocyte marker (GFAP). After incubation with specific fluorescence-labeled secondary antibodies, the slides were imaged by Leica TCS SP5 confocal system.
Immunofluorescence staining of HexA and LAMP2
Normal and TSD fibroblasts (GM01110) were seeded on cover glasses in 24-well plates and treated with PGRN (0.5 μg ml ) for 3 days. Cells were fixed with 4% formaldehydrate for 10 min, permeabilized by 0.1% Triton X-100 in PBS for 5 min, and blocked with donkey serum in PBS (1:50) for 1 h at room temperature. HexA antibody (1:100) and LAMP2 antibody (1:100), lysosomal markers, diluted in blocking buffer were added at 4°C overnight, followed by fluorescence-labeled secondary antibodies in blocking buffer (1:200), HexA with green color, and LAMP2 in red color, at 37°C for 1 h. After washing with PBS three times, the tissues were mounted with DAPI. The images were taken by immunofluorescence microscope.
Statistical analysis
Data are reported as the mean with standard error. Comparisons between the treatment groups were performed by unpaired two-tailed t tests in SPSS software (IBM, Armonk, NY, USA). p value < 0.05 was statistically significant.
Results
PGRN reduces lysosomal storage in patient fibroblasts from multiple LSDs
Previously, we identified PGRN as a novel factor in GD through its function as a co-chaperone required for GCase traffic to lysosome [28, 29] . PGRN and its small derivative, Pcgin, are therapeutic against GD in both in vitro and in vivo models [29] . In addition, PGRN's function as a chaperone may be a generalized mechanism to stabilize and deliver other lysosomal enzymes [29, 31, 37] . Therefore, we screened PGRN's potential therapeutic effect in multiple LSDs.
Using a lysotracker approach [29, 38] , we examined the effects of rPGRN on lysosomal storage in fibroblasts from healthy and patient donors affected by various LSDs, including GD. As expected, PGRN effectively reverted the altered lysosomes in fibroblasts from both types I and II GD with or without lipid challenge (Fig. 1a, b ). We were excited to observe that PGRN also remarkably normalized the altered lysosomes in Tay-Sachs disease, Farber's disease, and mucolipidosis III patient fibroblasts (Fig. 1a, b ). In line with these findings, the accumulation of glycosaminoglycan (GAG) and GM2 ganglioside was also observed in the tissues from aged PGRN-deficient mice (not shown). In the case of t y p e I I I G D , m u c o p o l y s a c h a r i d o s i s I I I , a n d mucopolysacharidosis VI, PGRN demonstrated beneficial effects only in the presence of lipid stimulation (Fig. 1c, d ).
PGRN treatment did not show significant improvements upon Niemann-Pick disease type B, Fabry disease, or mucolipidosis IV (Fig. 1e, f) , indicating selective effects of PGRN upon lysosomal storage pathologies. Taken together, these results suggest that PGRN, as a co-chaperone of the trafficking pathway, may be also involved in the lysosomal delivery of other lysosome enzymes in addition to GCase.
PGRN-deficient mice display the TSD-like phenotypes
The finding that PGRN is therapeutic in the fibroblasts of Tay-Sachs disease, together with our previous studies demonstrating that aged PGRN KO mice develop GDlike phenotypes spontaneously [28] and PGRN is therapeutic against in vivo and in vitro models of GD [29] , prompted us to see if PGRN insufficiency also causes a TSD phenotype. In 1-year-old aged PGRN KO mice, GM2 was aggregated in the brain tissues relative to aged WT mice, as detected by immunohistochemistry (IHC) staining and immunofluorescence staining of GM2 (Fig. 2a-c) . Under the electronic microscope, we observed tubular-like lysosomes in PGRN KO macrophages, a characteristic of GD phenotype, in addition to round multilayer membranous structures, called zebra bodies (Fig.  2d) , which correlate to GM2 ganglioside storage [39] . Since TSD is caused by mutation of the HexA gene, we examined whether HexA distribution is altered in PGRN KO mice after OVA challenge. Interestingly, IHC staining revealed that HexA was aggregated in PGRN KO mice, a similar observation to those we have reported previously concerning GCase [28] . HexB, however, displayed normal distribution which indicates that the aggregation of the HexA enzyme is specific (Fig. 2e) . Since HexA is aggregated in macrophages from peripheral organs in PGRN KO mice after OVA challenge, we also investigated whether OVA-challenged PGRN KO mice develop a TSD-like phenotype in brain tissues. GM2 expression was detected by IHC and immunofluorescence staining and GM2 was accumulated in brain tissues of PGRN KO mice after OVA challenge (Fig. 2f-h ). In brief, PGRN KO mice display components of the TSD-like phenotype spontaneously, with regard to the appearance of zebra bodies, and under stress-induced conditions, upon which GM2 accumulation is observable in brain tissues.
We next determined the cell types in the brains, including neuron, microglia, and astrocyte, in which GM2 accumulated. Briefly, we stained PGRN KO brain tissues with GM2 antibody, as well as antibodies against CD68, GFAP, or NeuN, the markers for microglia, astrocytes, and neuron, respectively. Confocal staining revealed that GM2 was not co-localized with either CD68 or GFAP, but highly co-localized with NeuN, indicating that GM2 is mainly accumulated in the neuron (Fig. 3a-c) .
PGRN increases the activities and lysosomal delivery of HexA
To elucidate the potential mechanisms of PGRN's effect in vitro, we treated TSD fibroblasts with lipid lysate to increase the lysosomal lipid load, and then treated the cells with PGRN protein. Under contrast microscopy, fibroblasts displayed a distinct change in morphology and lipid particles were observed attaching to cells after adding lipid lysate. PGRN-treated fibroblasts displayed notably less morphological alteration following lipid stimulation (data not shown). LysoTracker Red staining further revealed that lysosomal storage was significantly increased following lipid challenge, and it was reduced after PGRN treatment (Fig. 4a-c) . Immunofluorescence staining confirmed that GM2 was accumulated after lipid challenge and PGRN significantly decreased the lipid-induced fluorescence intensity of GM2 (Fig. 4d, e) . In addition, electronic microscope images demonstrated that lipid-induced enhanced zebra bodies and ER engorgement were largely corrected by recombinant PGRN (Fig. 4f) . Next, we examined whether PGRN regulated HexA level and enzymatic activity. After the application of PGRN in fibroblasts, the expression level of HexA, its activity, and, in particular, the lysosomal delivery of HexA were significantly elevated (Figs. 4g, h and 7) .
PGRN binds to HexA through granulins G and E
As PGRN could increase the activity of HexA, we sought to determine whether PGRN bound to HexA. Constructs expressing GFP-tagged PGRN and His-tagged HexA were cotransfected in 293T cells. After 24 h, cells were lysed with RIPA buffer and Co-IP assay was performed. The cell lysate was immunoprecipitated with His-tag antibody and probed by GFP antibody; results indicated that PGRN bound to HexA under this overexpression condition (Fig. 5a) . Next, we examined whether interaction between PGRN and HexA remained in native conditions using a Co-IP assay in RAW264.7 cells without transfection. We found this was the case (Fig. 5b) . Immunofluorescence staining, showing the co-localization of PGRN and HexA, further supported our Co-IP results and the conclusion that PGRN and HexA interact with each other (Fig. 5c) . To identify the binding site of PGRN to HexA, we first constructed C-and N-terminal deletion mutants of PGRN (Fig. 5d, g ). GFP-tagged PGRN and its deletion mutants and His-tagged HexA were co-transfected in 293T cells. After 24 h, cells were lysed and Co-IP was performed. PGRN and all the deletion mutants were successfully expressed after transfection as detected with a GFP antibody (Fig. 5e, h ). As shown in Fig. 5f , ND1 showed strong binding, and the binding was lost in ND2, which indicates granulin (GRN) G is one binding motif. With further deletion from the N-terminal, binding was restored in ND3 and the binding remained very strong in ND7, which is granulin E domain. Therefore, PGRN binds to HexA at two domains, Grn G and E. The same conclusion is drawn from C-terminal deletions; fulllength PGRN binds to HexA, while CD1, which features deletion of Grn E does not display HexA binding activity. Further deletions from the C-terminal show that CD6, which contains Grn-P-G, retains HexA binding activity and that the binding lost with deletion of Grn G (Fig.  5i) . This binding pattern is very similar to that observed in the PGRN-GCase interaction, in which PGRN binds to GCase through the Grn F and E domains [29] . As the Grn E domain contains chaperone activity and has been shown to bind to several lysosomal molecules, such GCase [29] , cathepsin D [37] , and sortilin [3] , we further investigated the binding motif important for HexA interaction within Grn E. 293T cells were transfected with serial deletions Δ1-Δ6 in Grn E and its linker region (Fig. 5j) , and Co-IP was performed; results revealed that the Δ4 (deletion of aa 540-573) fragment almost abrogated binding, indicating that the aa 540-573 sequence is critical for the binding between PGRN and HexA (Fig. 5k) .
Pcgin reduces GM2 storage in TSD fibroblasts in vitro
Pcgin is an engineered PGRN derivative bearing the granulin E domain that is capable of binding to HexA. We have shown that Pcgin binds to GCase and is therapeutic against GD [29] . Here, we sought to test whether Pcgin, similar to PGRN, is also therapeutic in TSD. Fibroblasts from TSD patients were cultured in 96-well plates or on cover slips in 24-well plates. Cells were treated with lipid or lipid plus Pcgin or lipid plus PGRN, as a positive control group. After 24 h, cells were stained with LysoTracker Red to measure lysosomal storage (Fig. 6a, b) . Lipid challenge significantly enhanced lysosomal storage, which was reduced following PGRN treatment, and Pcgin also effectively reduced LysoTracker staining (Fig. 6a, b) . To confirm the therapeutic effect of Pcgin, we measured GM2 level by immunofluorescence staining, and both Pcgin and PGRN reduced GM2 storage in TSD fibroblasts (Fig. 6c, d) . In another experiment, fibroblasts were seeded in 96-well plates, after ) increased HexA expression level in TSD fibroblasts. TSD fibroblasts were treated with PGRN for 3 days. The HexA protein levels were examined by Western blot. The figure is representative of three independent experiments. h PGRN enhanced HexA enzymatic activity in TSD fibroblasts. TSD fibroblasts were treated with PGRN (0.5 μg ml −1 ) for 3 days. The enzymatic activities were standardized by control group and measured by processing its specific substrate, MUGS. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 treatment with lipid, lipid plus PGRN or lipid plus Pcgin, the lysosomal storage was directly read by plate reader; both PGRN and Pcgin shown therapeutic effect in this assay as well (Fig.  6e) . Further, electronic microscope images demonstrated that lipid treatment-induced enhancement of zebra bodies and ER swelling were also corrected by recombinant Pcgin (Fig. 6f) . Since PGRN functions as a chaperone to stabilize HexA and enhance its enzymatic activity, next we examined whether Pcgin's therapeutic effect shared a similar mechanism. As shown in Fig. 6g , Pcgin treatment led to the induction of HexA expression at day 1, and particularly the increase of HexA enzymatic activity at all time points tested (Fig. 6h) . Therefore, the therapeutic effect of Pcgin appears to be carried out via a mechanism very similar to that of PGRN. Pcgin promotes the lysosomal delivery of HexA Our previously published data showed PGRN acted as a chaperone in Gaucher diseases to enhance the lysosomal delivery of GCase, together with the findings that both PGRN and Pcgin improve the GM2 storage in vitro and increase HexA activity, promoted us to determine whether Pcgin, similar to PGRN, also enhances HexA translocation to lysosome. To do so, we performed immunofluorescence staining of HexA and LAMP2, a lysosome marker. As demonstrated in Fig. 7 , both PGRN and Pcgin increased the lysosomal delivery of HexA in the patient GM01110 mutant fibroblasts.
Pcgin alleviates the GM2 accumulation in mouse model
Pcgin could reduce lysosomal storage and decrease the specific substrate of HexA in fibroblasts from TSD patients. Next, we examined whether Pcgin was also able to ameliorate TSD phenotypes in vivo. HexA KO mice are the current standard of TSD animal models and are not ideal for evaluation of the therapeutic efficacy of PGRN or Pcgin, since PGRN and Pcgin function through increasing mutated HexA's enzymatic activity and would be expected to have no effect in HexA KO mice. However, after OVA challenge, our PGRN KO mice displayed a typical TSD-like phenotype, including GM2 accumulation in the central nervous system and typical zebra body inclusions in macrophages as visualized under transmission electron microscopy (TEM). Therefore, we induced a TSD-like phenotype in PGRN KO mice via OVA challenge and treated mice with Pcgin (4 mg kg −1 week −1 ) or sterile vehicle by IP injection. The GM2 level in brain was examined by IHC and immunofluorescence staining (Fig. 8a-f) . IHC staining showed many GM2-positive plaques in the cortical region from mice in the OVA-challenged group; GM2 staining signal was reduced dramatically following Pcgin treatment (Fig. 8a, b) . To further confirm these results, sensitive immunofluorescence staining of GM2 was also conducted and results mirrored those of IHC staining (Fig. 8c, d ). These results were confirmed by highresolution confocal microscopy, and GM2 was accumulated in PGRN KO after OVA challenge and its level reduced following treatment of Pcgin (Fig. 8e, f) . Lipid ), processed for TEM. g The effects of Pcgin on HexA protein level in TSD fibroblasts. TSD fibroblasts were treated with Pcgin (5 μg ml −1 ) for 3 days. The HexA protein levels were examined by Western blotting. The figure is a representative of three independent experiments. h Pcgin enhanced HexA enzymatic activity in TSD fibroblasts. TSD fibroblast were treated with Pcgin (5 μg ml ) for 3 days. The enzymatic activities were standardized by control group and measured by processing its specific substrate, MUGS. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 composition analysis by mass spectrometry demonstrated that GM2 levels were higher in untreated PGRN KO brain than WT brain; however, OVA challenge significantly increased GM2 storage in the brain, and its level reduced following treatment with Pcgin (Fig. 8g) . Collectively, these data indicate that Pcgin was effective to reduce GM2 accumulation in both patient fibroblasts and animal models and might be a promising candidate to treat this devastating disease.
Discussion
PGRN consists of seven and a half repeats, P-G-F-B-A-C-D-E in order, of a cysteine-rich granulin motif, where the P domain is half-granulin, and the rest are full granulin domains [3, 23, 40, 41] . The granulins F, A, and C were identified as the binding domains of PGRN to TNFR [22] . Extracellular PGRN exerts anti-inflammatory function through binding to TNFR1 and inhibiting TNFα activity [22, 42, 43] and, in particular, through direct binding to and activating TNFR2 anti-inflammatory and protective signaling [11, 32, 44, 45] . Aside from important function in the extracellular space, emerging data have shown that intercellular PGRN is important for maintenance of lysosomal function [28, 29, 46, 47] . PGRN's importance in lysosome biology is demonstrated by the relationship between PGRN and LSDs; deficiency of PGRN associates with LSDs, including GD [28, 29] , neuronal ceroid lipofuscinosis [48, 49] , and TSD (this study). We have reported that PGRN functions as a chaperone molecule that facilitates GCase delivery to the lysosome, and this function is mediated through the C-terminal Grn E domain [29] . Further, a recent report has shown that PGRN stabilizes lysosomal enzyme cathepsin D through action of its C-terminal Grn E domain as a chaperone [37] . Therefore, PGRN is a shared chaperone molecule that facilitates multiple lysosomal enzyme activities [31] . When screening the therapeutic effect of PGRN in multiple LSDs, we were excited to find that PGRN was therapeutic in TSD, Farber's disease, and ML type 3, in addition to GD (Fig. 1a, b) . In aged PGRN KO mice or OVA-challenged adult PGRN KO mice, we found GM2 accumulation in the brain (Fig. 2) and typical zebra bodies in macrophages. Although accumulation of GM2 gangliosides is a common feature associated with a number of lysosomal storage diseases, including Niemann-Pick diseases, mucopolysaccharidoses, prosaposin deficiency, and ceroid lipofuscinoses [50] , we found that HexA, but not HexB, was specifically aggregated in PGRN KO mice (Fig. 2) . PGRN KO mice have mixed lipid storage in lysosomes, including lipofuscin, glucosylceramide, and GM2. It is noted that both PGRN or Pcgin significantly increased the HexA activity in the TSD fibroblasts but is still below the HexA activity in normal fibroblasts (data not shown). These results suggest that increasing the HexA activity might not be the major mechanism underlying PGRN/Pcgin-mediated therapeutic effects, other mechanisms, such as enhancing folding and lysosomal ) for 3 days were co-stained with HexA antibody (green) and LAMP2 antibody, a marker of lysosome (red). Results showed both PGRN and Pcgin increased the traffic of HexA to lysosome in the patient mutant GM01110 fibroblasts, indicated by white arrows. The images were taken under Leica confocal system, and the data shown is representative of three individual experiments delivery of mutant HexA, as it does for mutant GCase in Gaucher diseases, may be also important for PGRN's effects in TSD. Indeed, both PGRN and Pcgin increased the lysosomal delivery of HexA (Fig. 7) . These findings further support the concept that PGRN is a shared chaperone of lysosomal enzymes and plays an important role in the lysosome. In addition, PGRN KO mice might be useful for modeling multiple LSDs and for testing the therapeutic effects of potential LSD Fig. 8 Pcgin alleviates the GM2 accumulation in mouse model. a IHC staining of GM2 in paraffin-embedded brain tissue slides from PGRN KO mice challenged with OVA treated with or without Pcgin to detect the GM2 expression. GM2 was aggregated in PGRN KO mice challenged with OVA, and the application of Pcgin decreased GM2 accumulation. b The quantification of GM2 expression of (a). c Immunofluorescence staining of GM2 in paraffin-embedded brain tissue from PGRN knockout mice challenged with OVA treated with or without Pcgin. Fluorescent intensity was markedly increased in PGRN KO mice challenged with OVA, and Pcgin greatly reduced the fluorescence intensity. d The quantification of GM2 fluorescence intensity of (c). e Confocal staining of GM2 in frozen brain sections from PGRN KO mice, with or without OVA challenge (red, GM2; blue, DAPI). Pcgin alleviates GM2 storage. f The quantification of GM2 fluorescence intensity of (e). g Lipid analysis of GM2 levels in the brain tissues from WT and PGRN KO mice by mass spectrometry. Pcgin effectively reduced GM2 accumulation induced by OVA challenge. Data are reported as mean ± SEM. *P < 0.05; **P < 0.01 drugs. Although this study specifically focuses on the association of PGRN and its derivative Pcgin with TSD, the potential associations of PGRN/Pcgin with other LSDs, especially Farber's disease and mucolipidosis type III in which PGRN also showed potential therapeutic effects (Fig. 1) , warrant further investigations.
Interestingly, similar to PGRN binding to GCase, PGRN binds to HexA with two binding sites. Using serial deletions from the either the N-terminal or from C-terminal, we identified that PGRN binds to HexA through Grn G and E domains (Fig.  5f, i) . Grn E domain is a major protein-protein interaction domain for PGRN, as it has been shown to bind to GCase [29] , HSP70 [29] , cathepsin D [37] , and HexA (current report). Grn E binds to HSP70 and has chaperone activity, and we have found that Pcgin (containing Grn E and its C-terminal linker) has beneficial effect through facilitating lysosomal delivery of GCase [29] and enhancing HexA activity (this study). Grn E has also been shown to promote neurite growth in the central nervous system [51] . It is possible that Grn E promotion of neurite growth also relies on its chaperone activity, as HSP70 has been shown to promote neurite growth activity [52] . It is also noted that ND1 differs from FL PGRN and that all the ND series of constructs possess domain E, some of them (ND2 to ND5) have weak HexA interaction, but the smaller constructs ND6 and ND7 (domains D-E and E) have strong HexA interactions. These paradoxical results may suggest that small Nterminal peptide and other internal domain may inhibit the binding of PGRN to HexA via acting as the negative regulatory domains, or the structure of the mutants may be different, which also warrants further investigation.
The results that lysosomal storage phenotypes after ovalbumin stimulation was only observed in KO but not in WT macrophage and mice further indicate that PGRN pays a critical role in lysosome and keeps lysosome function normally in WT mice. Under stressed conditions, such as OVA challenge, and/or HexA mutations, HexA/PGRN complexes aggregate in the cytosol and may undergo protein degradation. Under such conditions, PGRN may be needed to recruit stressinduced HSP70 disaggregation system to HexA aggregates and to unlock the disaggregation of HexA aggregates, as we observed in Gaucher diseases [29] . TSD is a rare autosomal recessive genetic LSD caused by HexA gene mutations. TSD mainly affects the central nervous system and currently there are no effective treatments. Incidence of TSD at birth is low in general populations (carrier frequency 1 in 250) while mutations causing TSD are more common in particular communities. Ashkenazi Jewish is the most affected population with the carrier frequency is 1 in 25 [6] . Mutations in HexA gene have been reported to cause HexA protein undergo endoplasmic reticulum-associated degradation [53] , which results in reduction of HexA enzymatic activity and leads to GM2 accumulation in lysosomes. Here, we reported that both PGRN and Pcgin increase HexA enzymatic activities, possibly through facilitating the folding of HexA and stabilizing HexA protein.
Given that extracellular PGRN acts as a growth factor-like molecule, we cannot rule out the possibility that extracellular PGRN may affect the transcription, translation, post-translational modifications, synthesis, and degradation of HexA, also contributing to the increased levels and activity of HexA.
Pharmacological chaperones, the small molecules acting as competitive suppressors of their target enzyme, are reported to enhance enzyme activity. A good case in point is pyrimethamine, which was selected via drug library screening from 1040 compounds approved by the Food and Drug Administration and it has been used in an open-label phase I/II clinical trial. Pyrimethamine can improve HexA activity by up to fourfold at a dose of 50 mg day −1 or less [54] [55] [56] . Recently, Kato et al. reported that several carbohydrate motifs in HexA are activity-inhibiting sites. DMDP amide (6) and DNJNAc (1) can bind to these enzyme-inhibiting sites and stabilize HexA activity [57] . These reports suggest that chaperone-based therapy is a promising approach in the treatment of TSD. PGRN was also reported as a co-chaperone of HSP70 and is therapeutic in GD [29] . Here, we report both PGRN and its derivative, Pcgin, can enhance the HexA activity, which may account for, at least in part, their treatment effect in TSD.
In conclusion, by screening PGRN's effects on multiple LSDs, we identified TSD as a new LSD in which PGRN could effectively reduce the lysosomal storage and PGRN deficiency led to typical TSD phenotypes, including the existence of zebra bodies. The treatment effect of PGRN in TSD probably results from its binding to HexA, leading to the increased activity and lysosomal delivery of HexA. Pcgin, containing the E domain of PGRN, also showed lysosomal storage reduction ability in TSD. These findings not only provide new insights into the pathogenesis of TSD but also present evidences demonstrating that PGRN, and in particular the derivative Pcgin, may have potential for treating various kinds of lysosomal storage diseases, particularly TSD, a lifethreatening disease which currently has no cure.
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